Travere Therapeutics, Inc. - stock earnings
TVTX Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 6, 2024 AfterMarket | -1.18 / -0.99 | - | - / 45.3 million | - |
TVTX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -90.2 million USD | 45.1 million USD |
| 2023Q3 | 150.7 million USD | 37.1 million USD |
| 2023Q2 | -85.6 million USD | 59.7 million USD |
| 2023Q1 | -86.3 million USD | 57.0 million USD |
| 2022Q4 | -65.8 million USD | 55.9 million USD |
| 2022Q3 | -69.7 million USD | 53.5 million USD |
| 2022Q2 | -67.0 million USD | 54.2 million USD |
| 2022Q1 | -76.0 million USD | 48.5 million USD |
| 2021Q4 | -51.6 million USD | 57.2 million USD |
| 2021Q3 | -35.6 million USD | 68.2 million USD |
| 2021Q2 | -39.0 million USD | 54.6 million USD |
| 2021Q1 | -53.9 million USD | 47.4 million USD |
| 2020Q4 | -121.6 million USD | 51.0 million USD |
| 2020Q3 | -22.5 million USD | 51.1 million USD |
| 2020Q2 | -26.1 million USD | 48.4 million USD |
| 2020Q1 | 808000 USD | 47.8 million USD |
| 2019Q4 | -30.3 million USD | 46.7 million USD |
| 2019Q3 | -36.5 million USD | 44.4 million USD |
| 2019Q2 | -38.7 million USD | 44.7 million USD |
| 2019Q1 | -41.0 million USD | 39.6 million USD |
| 2018Q4 | -7.5 million USD | 43.8 million USD |
| 2018Q3 | -54.5 million USD | 40.7 million USD |
| 2018Q2 | -22.3 million USD | 41.3 million USD |
| 2018Q1 | -18.4 million USD | 38.4 million USD |
| 2017Q4 | -17.6 million USD | 42.2 million USD |
| 2017Q3 | -17.8 million USD | 40.3 million USD |
| 2017Q2 | -13.2 million USD | 38.8 million USD |
| 2017Q1 | -11.1 million USD | 33.6 million USD |
| 2016Q4 | -8.6 million USD | 37.3 million USD |
| 2016Q3 | -37.1 million USD | 33.9 million USD |
| 2016Q2 | -13.4 million USD | 33.3 million USD |
| 2016Q1 | 11.2 million USD | 29.0 million USD |
| 2015Q4 | -2.5 million USD | 30.4 million USD |
| 2015Q3 | 105.6 million USD | 28.0 million USD |
| 2015Q2 | -25.5 million USD | 24.1 million USD |
| 2015Q1 | 39.7 million USD | 17.4 million USD |
| 2014Q4 | -29.2 million USD | 14.1 million USD |
| 2014Q3 | -19.6 million USD | 8.3 million USD |
| 2014Q2 | 8.5 million USD | 5.7 million USD |
| 2014Q1 | -70.6 million USD | 27900 USD |
| 2013Q4 | -13.1 million USD | ? USD |
| 2013Q3 | -10.9 million USD | ? USD |
| 2013Q2 | -4.7 million USD | ? USD |
| 2013Q1 | -4.7 million USD | ? USD |
| 2012Q4 | -3661 USD | ? USD |
| 2012Q3 | -3500 USD | ? USD |
| 2012Q2 | -3509 USD | ? USD |
| 2012Q1 | -4258 USD | ? USD |
| 2011Q4 | -3518 USD | ? USD |
| 2011Q3 | -3525 USD | ? USD |
| 2011Q2 | -3524 USD | ? USD |
| 2011Q1 | -4080 USD | ? USD |
| 2010Q4 | -5672 USD | ? USD |
| 2010Q3 | -3376 USD | ? USD |
| 2010Q2 | -6626 USD | ? USD |
TVTX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -111.4 million USD | 145.2 million USD |
| 2022 | -278.5 million USD | 212.0 million USD |
| 2021 | -180.1 million USD | 227.5 million USD |
| 2020 | -169.4 million USD | 198.3 million USD |
| 2019 | -146.4 million USD | 175.3 million USD |
| 2018 | -102.7 million USD | 164.2 million USD |
| 2017 | -59.7 million USD | 154.9 million USD |
| 2016 | -47.9 million USD | 133.6 million USD |
| 2015 | 117.2 million USD | 99.9 million USD |
| 2014 | -110.9 million USD | 28.2 million USD |
| 2013 | -33.8 million USD | ? USD |
| 2012 | -30.3 million USD | ? USD |
| 2011 | -14825 USD | ? USD |
| 2010 | -18266 USD | ? USD |
TVTX
Price: $6.26
52 week price:
Earnings Per Share: -5.07 USD
P/E Ratio: -1.88
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Market Capitalization: 476.4 million